U.S. markets close in 4 hours 1 minute

  • S&P 500

    3,920.27
    +8.53 (+0.22%)
     

  • Dow 30

    31,566.46
    +65.78 (+0.21%)
     

  • Nasdaq

    11,590.58
    -17.04 (-0.15%)
     

  • Russell 2000

    1,781.12
    +15.38 (+0.87%)
     

  • Crude Oil

    109.23
    +1.61 (+1.50%)
     

  • Gold

    1,824.80
    -5.50 (-0.30%)
     

  • Silver

    21.26
    +0.14 (+0.64%)
     

  • EUR/USD

    1.0604
    +0.0046 (+0.43%)
     

  • 10-Yr Bond

    3.1900
    +0.0650 (+2.08%)
     

  • GBP/USD

    1.2303
    +0.0033 (+0.27%)
     

  • USD/JPY

    135.3010
    +0.1310 (+0.10%)
     

  • BTC-USD

    20,773.83
    -553.38 (-2.59%)
     

  • CMC Crypto 200

    452.54
    -9.26 (-2.00%)
     

  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     

  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Wolf announces public-private partnership on hydrogen hub

Paul J. Gough
·2 min read
Wolf announces public-private partnership on hydrogen hub
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • EQT
  • X

Gov. Tom Wolf on Monday announced a statewide initiative to secure a hydrogen hub and large-scale carbon storage system in Pennsylvania in an effort to gain a share of $8 billion in federal funding for such efforts. The Wolf administration also announced it had signed a declaration with 24 companies and nonprofits on the transition to decarbonization, including the major players in the Pittsburgh region including Shell Chemical, EQT Corp. (NYSE: EQT) and United States Steel Corp. (NYSE: X) that have banded together for a public private partnership.

Continue reading

Recommended Stories

  • Why Axsome Therapeutics Stock Is On Fire Today

    Axsome Therapeutics (NASDAQ: AXSM), a newly minted commercial-stage biopharma, is set for a strong session today. Ahead of the opening bell this morning, Axsome released an 8-K filing with the Securities and Exchange Commission revealing that it has received the proposed labeling from the Food and Drug Administration (FDA) for the experimental major depressive disorder drug known as AXS-05. The FDA reportedly sent Axsome this long-awaited regulatory update last Friday.

  • 3 Reasons to Buy Novavax and 1 to Sell

    Novavax (NASDAQ: NVAX) is a pandemic stock. Now it's down to $50, and the company's market cap is under $4 billion. Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.

  • Robert Kiyosaki says that hot inflation will 'wipe out 50% of the US population' — here's what he means by that and how to protect yourself

    'Rich Dad Poor Dad' is more bearish than ever.

  • Plug Power bought a company for $123 million. That investment is about to become its biggest business

    "One of the reasons the sales funnel for electrolyzers continues to grow is because of the atrocities that are happening in Ukraine," says Plug Power chief executive Marsh.

  • Should You Consider Investing in NIO?

    Horos Asset Management, an investment management firm, published its first-quarter 2022 investor letter – a copy of which can be downloaded here. Since the inception of Horos (May 21, 2018), Horos Value Internacional has returned 22.3%, below the 55.2% gain of its benchmark, while Horos Value Iberia has returned 8.1%, outperforming the 0.5% return of […]

  • 11 Best Undervalued Stocks to Buy Now

    In this article, we will look at 11 best undervalued stocks to buy now. If you want to explore similar stocks, you can also read 5 Best Undervalued Stocks to Buy Now. Value investing has long been an investors’ go-to strategy to come atop the broad market and pocket huge profits for themselves and their […]

  • Trump-Tied SPAC Tumbles After Disclosing Grand Jury Subpoena

    (Bloomberg) -- Digital World Acquisition Corp., the special purpose acquisition company merging with Trump Media & Technology Group, tumbled after disclosing that a federal grand jury in the Southern District of New York issued subpoenas to the company and members of its board of directors. Most Read from BloombergRussia Slips Into Historic Default as Sanctions Muddy Next StepsHyundai Quietly Climbs the EV Sales Charts and Elon Musk NoticesRep. Mary Miller Calls Roe Decision ‘Victory for White L

  • Jim Cramer Recommends These 10 Stocks for Recession

    In this article, we discuss the 10 stocks that Jim Cramer recommends for recession. If you want to read about some more stocks that Jim Cramer recommends for recession, go directly to Jim Cramer Recommends These 5 Stocks for Recession. Recession fears have steadily been gathering pace at the stock market over the past few […]

  • Should Investors Be Worried After Palantir's Q1 Earnings?

    Palantir's first-quarter results got a mixed review from investors, but the underlying fundamentals offer some encouragement.

  • Teva Pharmaceutical Industries (NYSE:TEVA) investors are sitting on a loss of 76% if they invested five years ago

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

  • Bank of America Could Lose $44 Billion in a Severe Recession. Should Investors Be Worried?

    The Federal Reserve recently released the results of its annual stress testing, in which it puts the largest banks in the country through a set of hypothetical severe economic conditions akin to a severe recession. This year, the Fed was not messing around. Between the fourth quarter of 2021 and through the first quarter of 2024, the Fed's hypothetical scenario included unemployment rising above 10%, commercial real estate prices dropping 40%, and stock prices dropping 55%.

  • Tesla Has a New Rival on the Rise

    The maker of premium and high-end electric vehicles remains the market leader in electric vehicles but sees a threatening rival.

  • Russia, rejecting default, tells investors to go to western financial agents

    The White House said on Monday that Russia has defaulted on its international bonds for the first time since the Bolshevik revolution, as sweeping sanctions have effectively cut the country off from the global financial system. Until last week, Russia kept on paying on its Eurobonds in foreign currency as per issue conditions yet its dollar and euro coupon transfers made in May, ahead of a key U.S. waiver allowing for such transactions expired, did not reach investors. "Statements of a default are absolutely unjustified," Kremlin spokesperson Dmitry Peskov told a call with reporters on Monday, pointing to the May forex coupon payment.

  • 3 Stocks That Could Help Set You Up for Life

    A strange thing is happening on Wall Street: After months of falling stock prices and rising pessimism, some respected analysts are predicting that technology stocks have bottomed. Analysts expect it to generate an earnings per share of $3.44 this year and $4.53 next year.

  • Bristol-Myers Squibb Company (NYSE:BMY) Stock Goes Ex-Dividend In Just Two Days

    Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Bristol-Myers...

  • ‘A cold dark place’ — Michael Burry thinks the market has plenty of room to plunge. But he finally sees value in these 4 stocks

    Burry’s not bullish. But he’s beginning to nibble.

  • 10 Stocks You Should Sell in 2022 According to Billionaire Dan Loeb

    In this article, we will look at 10 stocks you should sell in 2022 according to billionaire Dan Loeb. If you want to skip reading about Dan Loeb’s view on the current market situation and his hedge fund’s performance, you can go directly to 5 Stocks You Should Sell in 2022 According to Billionaire Dan […]

  • Is AbbVie About To Get A New Blockbuster Drug?

    AbbVie recently applied for FDA approval of its advanced Parkinson's disease drug candidate. This could be huge considering it's set to lose market exclusivity of Humira.

  • The Secret to Retiring Comfortably at 62

    Age 62 is the first year you're eligible for Social Security, but your benefit amount will lower. We go over how to retire comfortably at 62.

  • No Government Money, No Problem for Moderna and Pfizer

    Congressional gridlock on Covid-19 funding might lead to vaccine inequity, but it won’t be a bad thing for the manufacturers, which will charge a higher price in the private market.